生物技術領域合作協議（2021-2026）

讓我們了解生技公司如何透過合作利用自身能力來推動創新，並創造研發和商業化機會。

《生物技術領域的合作協議》提供了有關 1,702 項涉及生物技術公司的合作協議的全面資訊。

本報告分析了生物技術公司如何透過合作協議將其技術、專業知識、開發能力和商業資源與外部合作夥伴的技術、專業知識、開發能力和商業性資源整合起來。

此類合作關係可以在推進新興技術和治療資產、獲取內部可能不存在的能力、分擔開發風險以及為後期開發和商業化鋪平道路方面發揮關鍵作用。

該報告不僅列出了交易，還幫助用戶了解誰是合作夥伴、合作活動集中在哪些地區、協議的結構如何，以及可以從披露的財務條款和公開的合約文件中了解什麼。

本報告為生物技術領域的業務發展、許可、研究和評估、公司策略、研發策略、合作夥伴關係管理以及負責人合作夥伴關係的法律團隊提供可操作的資訊和基準資源。

了解生物技術領域的合作趨勢。

本報告分析了2021年至2026年的合作協議，內容包括：

• 合作專案年度趨勢
• 合作關係發展階段
• 產業部門
• 治療區域
• 技術類型
• 最活躍的合作夥伴談判公司
• 根據已揭露的交易金額，主要交易金額
• 簽訂合作協議的策略性原因
• 生物技術領域合作策略的演變
• 這使用戶能夠看到合作活動集中在哪些方面，確定哪些技術和治療領域正在吸引合作的關注，並了解哪些公司最積極參與外部創新。
• 了解合夥協議的結構
• 生物技術領域的合作協議涵蓋了從早期研究夥伴關係和技術合作到更廣泛的開發和商業化合作。

本報告提供以下信息，幫助使用者探索以下領域：

• 研發職責
• 授予或可選的權利
• 發展資金和成本分配
• 智慧財產權所有權和許可權
• 管治與決策
• 獨家條款
• 負責開發和監管
• 製造和供應
• 商業化方面的權利和責任
• 與該地區和市場相關的權利
• 如已揭露，財務狀況如下：
• 合約期限和終止條款
• 對於正在考慮合作框架或準備合作談判的公司來說，這將是一個有用的參考資料。
• 對標關鍵交易案例和已揭露的財務條款
• 本報告根據已揭露的交易價值確定了重要的生物技術合作夥伴關係，並提供了與每項協議相關的可用財務資訊。

用戶可以查看以下公開內容：

• 預付款
• 開發和監管里程碑
• 商業化里程碑
• 特許權使用費協議
• 股票投資
• 研究經費
• 其他可用的財務承諾
• 這樣一來，用戶可以將他們正在考慮的交易與生物技術領域類似的真實合作案例進行比較，從而為準備和談判交易建立更準確的基準。
• 確定生物技術領域合作談判的負責人。
• 本報告重點介紹了最積極達成合作協議的前 25 家公司，深入分析了那些反覆利用夥伴關係來獲取和開發技術及資產的公司。

個別交易記錄有助於了解特定公司如何參與外部創新，並支持以下方面：

• 尋找合作夥伴
• 調查與評估
• 競爭對手分析
• 業務發展策略
• 夥伴關係活動評估
• 對於尋求開發或商業合作夥伴的生物技術公司而言，這也有助於確定對特定技術、治療領域或開發階段有明確興趣的組織。
• 從實際合約文件中學習
• 本報告提供了公開可用的相關合作協議文件。
• 這些協議揭示了僅憑公司新聞稿無法獲得的詳細信息，使用戶能夠檢驗選定的合作夥伴如何處理開發義務、知識產權、排他性、管治、財務安排、商業化權利和合約終止等事項。
• 對於正在準備或談判合作協議的團隊來說，這些實際合約提供了寶貴的見解，讓我們得以了解類似的生物技術合作關係是如何實際記錄的。
• 綜合合作夥伴名錄
• 本報告包含 1702 項生物技術合作的綜合目錄，使用戶能夠找到與其資產、技術和合作目標相關的交易。

交易記錄可依以下類別查看：

• 公司
• 治療區域
• 技術類型
• 合約揭露狀態
• 每筆交易都與其底層交易記錄關聯，從而可以存取詳細的交易資訊和相關的合約文件（如有）。
• 誰該使用這份報告？
• 業務拓展與授權團隊
• 在製定合作策略時，我們會尋找類似的合作案例、潛在的合作夥伴以及相關的交易結構。
• 研究與評估團隊
• 我們識別出活躍於特定技術、治療領域和發展階段的公司，並調查其過去的合作活動。
• 生物技術管理團隊
• 我們將了解競爭對手如何利用夥伴關係來確保研發能力、資金籌措和明確的商業化路徑。
• 企業策略與研發策略團隊
• 該報告追蹤了生物技術公司如何利用外部合作夥伴關係來補充其內部技術、資產和能力。
• 合作夥伴關係管理團隊
• 我們將檢驗在類似的合作關係中，責任、管治和對合作夥伴的持續義務是如何建構的。
• 法律及交易團隊
• 我們將仔細審查交易結構和公開的合約條款，以協助您準備和談判交易。
• 競爭與市場情報團隊
• 我們按公司、治療領域、技術和開發階段分析合作活動，以識別重要的合作趨勢。
• 我們將整體市場資訊轉化為針對每家公司的具體洞察。
• 對於符合資格的客戶，Current Partnering 不僅會提供報告，還會為高階主管提供客製化的合作關係簡報。
• 本簡報將說明有關生物技術領域合作的基礎信息，並根據您自己的業務、技術、資產或合作目標量身定做。
• 如有需要，我們還可以提供相關的類似交易、有前景的潛在合作夥伴、競爭對手的活動、交易結構、財務基準、合約見解以及其他專門為您的合作情況選擇的資訊。
• 請索取樣本或聯絡 Current Partnering 討論本報告的內容以及我們是否可以為貴公司提供客製化分析。

目錄

執行摘要

第1章：引言

第2章：合作交易的趨勢

• 介紹
• 合作協議的定義
• 合作協議的趨勢
• 簽訂合夥協議的理由
• 協作交易的未來

第3章：合作協議結構概述

• 介紹
• 合作協議的結構

第4章 主要合作協議

• 介紹
• 按以金額為準的頂級合作項目

第5章：合作交易最活躍的25家公司

• 介紹
• 合作交易最活躍的前 25 家公司

第6章 合作協議（包括合約）

• 介紹
• 合夥協議
• 特價優惠列表
• 交易目錄 - 公司特定協作交易 AZ
• 交易目錄 - 按治療領域分類的合作交易
• 交易目錄 - 按技術類型分類的協作交易
• 關於 Biopharma Research Ltd.
• Current Partnering
• 目前合約
• 最新報告標題

Understand how biotechnology companies use collaboration partnerships to access capabilities, advance innovation and create development and commercialization opportunities.

Collaboration Deals in Biotechnology provides comprehensive intelligence on 1,702 collaboration deals involving biotechnology companies.

The report examines how biotech companies use collaboration agreements to combine technologies, expertise, development capabilities and commercial resources with those of external partners.

These partnerships can play a critical role in advancing emerging technologies and therapeutic assets, accessing capabilities that may not exist internally, sharing development risk and creating routes towards later-stage development and commercialization.

Rather than simply identifying transactions, the report enables users to understand who is collaborating, where partnering activity is concentrated, how agreements are structured, and what can be learned from disclosed financial terms and publicly available contract documents.

It provides a practical intelligence and benchmarking resource for business development, licensing, search and evaluation, corporate strategy, R&D strategy, alliance management and legal teams involved in biotechnology partnering.

Understand the biotechnology collaboration landscape

The report analyzes collaboration dealmaking from 2021 to 2026, including:

• Trends in collaboration dealmaking by year
• Stage of development at the time of partnering
• Industry sector
• Therapy area
• Technology type
• Most active collaboration dealmakers
• Leading deals by disclosed value
• Strategic reasons for entering collaboration agreements
• How biotechnology collaboration strategies are evolving
• This enables users to see where collaboration activity is concentrated, identify technologies and therapeutic areas attracting partnership activity and understand which companies are most actively engaging with external innovation.
• Understand how collaboration agreements are structured
• Biotechnology collaboration agreements can range from early research partnerships and technology collaborations through to broader development and commercialization alliances.

The report provides intelligence to help users examine areas including:

• Research and development responsibilities
• Rights granted or optioned
• Development funding and cost allocation
• Intellectual property ownership and licensing rights
• Governance and decision-making
• Exclusivity provisions
• Development and regulatory responsibilities
• Manufacturing and supply
• Commercialization rights and responsibilities
• Geographic and market rights
• Financial terms where disclosed
• Term and termination provisions
• This provides useful reference points for companies considering potential collaboration structures or preparing for partnering discussions.
• Benchmark leading deals and disclosed financial terms
• The report identifies leading biotechnology collaboration transactions by disclosed deal value and provides access to available financial information associated with individual agreements.

Users can investigate disclosed elements including:

• Upfront payments
• Development and regulatory milestones
• Commercial milestones
• Royalty arrangements
• Equity investments
• Research funding
• Other financial commitments where available
• This enables users to place potential transactions into the context of comparable real-world biotechnology collaborations and establish more informed benchmarks for deal preparation and negotiation.
• Identify leading biotechnology collaboration dealmakers
• The report profiles the Top 25 most active collaboration dealmakers, providing insight into companies that repeatedly use collaboration partnerships to access or develop technologies and assets.

Individual deal histories can help users understand how specific companies approach external innovation and can support:

• Partner identification
• Search and evaluation
• Competitor analysis
• Business development strategy
• Assessment of partnering behaviour
• For biotechnology companies seeking development or commercial partners, this can also help identify organizations with a demonstrated appetite for particular technologies, therapeutic areas or stages of development.
• Learn from real-world contract documents
• Where publicly available, the report provides access to underlying collaboration contract documents.
• These agreements can reveal substantially more detail than company announcements alone, enabling users to examine how selected partners have addressed areas such as development obligations, intellectual property, exclusivity, governance, financial arrangements, commercialization rights and termination.
• For teams preparing for or negotiating collaboration agreements, these real-world contracts provide valuable insight into how comparable biotechnology partnerships have been documented in practice.
• Comprehensive collaboration deal directory
• The report includes a comprehensive directory of 1,702 biotechnology collaboration deals, allowing users to identify transactions relevant to their own assets, technologies and partnering objectives.

Deals can be reviewed by:

• Company
• Therapy area
• Technology type
• Contract availability
• Individual transactions are linked to their underlying deal records, providing a route to further deal information and associated contract documentation where available.
• Who should use this report?
• Business Development and Licensing teams
• Identify comparable collaborations, potential partners and relevant transaction structures when developing partnering strategies.
• Search and Evaluation teams
• Identify companies active in specific technologies, therapeutic areas and development stages and investigate their previous partnering activity.
• Biotechnology Management teams
• Understand how peer companies are using collaboration partnerships to access development capabilities, funding and routes towards commercialization.
• Corporate and R&D Strategy teams
• Track how biotechnology companies are using external partnerships to complement internal technologies, assets and capabilities.
• Alliance Management teams
• Examine how responsibilities, governance and ongoing partner obligations have been structured across comparable collaborations.
• Legal and Transaction teams
• Review deal structures and publicly available contract language to support transaction preparation and negotiation.
• Competitive and Market Intelligence teams
• Analyze collaboration activity by company, therapy area, technology and stage of development to identify important partnering trends.
• Turn market-wide intelligence into company-specific insight
• For qualifying customers, Current Partnering can also provide a Customized Executive Partnering Briefing alongside the report.
• The briefing applies the underlying biotechnology collaboration intelligence to the customer's own business, technologies, assets or partnering objectives.
• Depending on requirements, this can include relevant comparable deals, prospective partners, competitor activity, deal structures, financial benchmarks, contract insights and other intelligence selected specifically for the client's partnering situation.
• Request a sample or contact Current Partnering to discuss the report and whether a customized analysis can be provided for your organization.

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in collaboration dealmaking

• 2.1. Introduction
• 2.2. Definition of collaboration deal
• 2.3. Trends in collaboration deals
  • 2.3.1. Collaboration dealmaking by year
  • 2.3.2. Collaboration dealmaking by phase of development
  • 2.3.3. Collaboration dealmaking by industry sector
  • 2.3.4. Collaboration dealmaking by therapy area
  • 2.3.5. Collaboration dealmaking by technology type
  • 2.3.6. Collaboration dealmaking by most active company
• 2.4. Reasons for entering into collaboration partnering deals
• 2.5. The future of collaboration deals

Chapter 3 - Overview of collaboration deal structure

• 3.1. Introduction
• 3.2. Collaboration agreement structure

Chapter 4 - Leading collaboration deals

• 4.1. Introduction
• 4.2. Top collaboration deals by value

Chapter 5 - Top 25 most active collaboration dealmakers

• 5.1. Introduction
• 5.2. Top 25 most active collaboration dealmakers

Chapter 6 - Collaboration deals including contracts directory

• 6.1. Introduction
• 6.2. Collaboration deals with contracts
• Deal directory
• Deal directory - collaboration dealmaking by companies A-Z
• Deal directory - collaboration dealmaking by therapy area
• Deal directory - collaboration dealmaking by technology type
• About Biopharma Research
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

TABLE OF FIGURES

• Figure 1: Definition of collaboration deal
• Figure 2: Trends in collaboration deal announcements
• Figure 3: Collaboration deals signed at each phase of development
• Figure 4: Collaboration deals by industry sector
• Figure 5: Collaboration deals by therapy area
• Figure 6: Collaboration deals by technology type
• Figure 7: Top 25 most active collaboration dealmakers
• Figure 8: Top collaboration deals by value
• Figure 9: Most active collaboration dealmakers